# Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer

> **NCT05771584** · PHASE2 · RECRUITING · sponsor: **Aston Sci. Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** AST-301
- **DRUG:** rhuGM-CSF

## Key facts

- **NCT ID:** NCT05771584
- **Lead sponsor:** Aston Sci. Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-04
- **Primary completion:** 2025-10-15
- **Final completion:** 2026-06-15
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05771584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05771584, "Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05771584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*